U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801015) titled 'Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions' on Jan. 24.
Brief Summary: The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.
Study Start Date: April 15, 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: Semaglutide
Both interventions are approved by FDA for the treatment of obesity and are a...